Juvenile Parkinsonism: Early-Onset Parkinson's in Children and Adolescents

Epidemiology

  • Incidence: ~0.1-0.5 per 100,000 children/year (vs. ~150/100,000 in >60 years).
  • Age Definitions: Juvenile (<21 years), Young-Onset (21-40), Late-Onset (>40).
  • Genetic Proportion: >50% juvenile cases have identifiable mutations vs. ~10-15% adult-onset.

Genetic Etiologies

GeneInheritanceOnsetFeatures
PRKN (PARK2)Autosomal RecessiveJuvenile (mean 16)Most common; slow progression; dystonia; good levodopa response; cognitive sparing
PINK1 (PARK6)AREarly adulthoodSimilar to PRKN; mitochondrial quality control defect
DJ-1 (PARK7)ARYoungRare; psychosis, cognitive features possible
SNCA (PARK1/4)Autosomal DominantYoung-adultα-synuclein multiplication; rapid progression; dementia
LRRK2 (PARK8)ADVariable (can be juvenile)Most common genetic PD overall; incomplete penetrance
VPS35, CHCHD2, DNAJC13ADAdult/YoungRare; vesicular trafficking, mitochondrial

Clinical Presentation

  • Classic triad: Bradykinesia + Rigidity + Rest Tremor (may be absent initially).
  • Atypical Features in Juvenile: Dystonia (especially foot inversion), gait disturbance, cognitive/behavioral issues, psychiatric comorbidities.
  • Non-Motor: Sleep disorders, autonomic dysfunction, sensory symptoms, mood disorders – often precede motor signs.

Diagnostic Workup

  1. Clinical: Detailed history, neurological exam (UPDRS), family pedigree.
  2. Genetic Testing: Panel (PRKN, PINK1, DJ-1, SNCA, LRRK2, VPS35) + CMA/WES if negative.
  3. Imaging: DaTscan (dopamine transporter SPECT) – confirms dopaminergic deficit; MRI (exclude structural).
  4. Levodopa Challenge: Dramatic response supports diagnosis.

Management

Pharmacologic

  • Levodopa/Carbidopa: Gold standard; start low (50-100 mg/day); juvenile patients often highly sensitive → dyskinesias.
  • Dopamine Agonists: Pramipexole, ropinirole, rotigotine – delay levodopa; impulse control risk.
  • MAO-B Inhibitors: Rasagiline, selegiline – mild benefit, neuroprotective potential.
  • Anticholinergics: Trihexyphenidyl – for tremor/dystonia; cognitive side effects limit use.

Advanced Therapies

  • DBS (Deep Brain Stimulation): STN or GPi; considered for motor fluctuations/dyskinesias refractory to meds. Age not absolute barrier.
  • Infusion Therapies: Duopa (levodopa/carbidopa intestinal gel), apomorphine pump.

Multidisciplinary Care

  • Pediatric/adult movement disorder neurologist, PT/OT/SLT, neuropsychology, genetics, social work, education liaison.
  • School accommodations (IEP/504): fatigue management, motor breaks, assistive tech.

Prognosis

  • Generally slower progression than adult-onset; decades of functional independence common.
  • Genotype influences trajectory (PRKN > LRRK2 > SNCA).
  • Lifespan near-normal with modern management.

Juvenile parkinsonism is a distinct entity requiring genetic diagnosis, age-tailored treatment, and lifespan care planning. Early specialist referral optimizes outcomes.

Pediatrics - Related Articles